Pfizer has faced lawsuits on four major fronts: state attorney general challenges to its COVID-19 vaccine marketing, federal fraud and False Claims Act cases, product liability claims tied to specific drugs, and antitrust disputes over pricing and market entry. Since 2000, the company has paid more than $11 billion in penalties and settlements across 108 enforcement actions, ranking third among pharmaceutical companies by total exposure.1Good Jobs First. Pfizer Violation Tracker Some of the largest Pfizer lawsuits are decades old and long resolved; others are active right now, including multidistrict litigation over Depo-Provera, state consumer protection suits in Texas and Kansas, and antitrust cases Pfizer itself has filed against Novo Nordisk.
Active COVID-19 Vaccine Cases
Texas
Texas Attorney General Ken Paxton sued Pfizer on November 30, 2023, alleging violations of the Texas Deceptive Trade Practices Act. The complaint claimed Pfizer misrepresented the vaccine’s efficacy by leaning on relative risk reduction to promote a 95% figure, misled the public about how long protection lasted, and failed to measure whether the vaccine prevented transmission while urging people to get vaccinated to protect others. Paxton also alleged Pfizer conspired to censor criticism of the vaccine on social media.2Texas Attorney General. Attorney General Ken Paxton Sues Pfizer for Misrepresenting COVID-19 Vaccine Efficacy and Conspiring to Censor Public Discourse
On December 30, 2024, Senior Judge Sam Cummings of the U.S. District Court for the Northern District of Texas granted Pfizer’s motion to dismiss. The court found Pfizer immune under the federal Public Readiness and Emergency Preparedness Act and ruled that the statements Texas challenged were not connected to trade, commerce, or a consumer transaction.3Bloomberg Law. Pfizer Defeats Texas Lawsuit Over COVID Vaccine Effectiveness Paxton filed a notice of appeal on January 8, 2025, and the case remains active on appeal.4Texas Attorney General. Attorney General Ken Paxton Continues Lawsuit Against Pfizer for Knowingly Misrepresenting Efficacy
Kansas
Kansas Attorney General Kris Kobach filed a separate suit in June 2024 in Thomas County District Court under the Kansas Consumer Protection Act. The complaint targets Pfizer’s “safe and effective” marketing and alleges the company concealed information about vaccine safety for pregnant women, myocarditis and pericarditis risks, effectiveness against variants, and effect on transmission.5Kansas Reflector. Kansas AG Kobach Accuses Pfizer of Misleading Vaccine Marketing in Lawsuit
Pfizer removed the case to federal court, but on May 14, 2025, Judge Daniel Crabtree of the U.S. District Court for the District of Kansas remanded it back to state court, holding that the matter belonged in the state system.6Kansas Attorney General. AG Kobach’s Consumer Protection Case Against Pfizer Remanded to State Court Pfizer has indicated the remand may be appealed. As of mid-2025 the case is proceeding in Thomas County.7KCTV5. Case Filed Against Pfizer Over COVID Vaccine Marketing to Be Heard at State Level
If You Were Injured by a COVID-19 Vaccine
Individual injury lawsuits against Pfizer over the COVID-19 vaccine face a steep barrier. The PREP Act, invoked by the HHS Secretary in February 2020, grants manufacturers broad immunity from liability for injuries tied to COVID-19 medical countermeasures unless there is evidence of willful misconduct. That immunity covers both FDA-licensed and emergency-use-authorized vaccines.8Congressional Research Service. COVID-19 Vaccines Legal Issues The primary compensation route is the government-run Countermeasures Injury Compensation Program, which covers unreimbursed medical expenses and lost wages but not pain, suffering, or attorney fees.9CNBC. COVID Vaccine Side Effects Compensation Lawsuit
Depo-Provera Brain Tumor MDL
The largest active product liability litigation against Pfizer involves the long-acting contraceptive Depo-Provera. Plaintiffs allege the drug is linked to intracranial meningiomas, a type of brain tumor, and that Pfizer failed to warn about the risk. As of early 2026, more than 2,100 lawsuits have been consolidated into a multidistrict litigation, a fivefold increase since May 2025. The first bellwether trial is scheduled for December 2026 before District Judge M. Casey Rodgers.10ICLG. Pfizer Faces 2026 Trial as Brain Tumour Claims Multiply
The claims draw on a March 2024 study in the British Medical Journal and a 2025 U.S. study of 60 million women, both indicating elevated meningioma risk for users of four years or longer. The FDA approved updated Depo-Provera labeling in late 2025 and early 2026 to include a specific warning about intracranial meningioma. Pfizer has not admitted liability and has pointed out that warning labels had already been updated in the UK, Canada, and parts of Europe before the FDA change.10ICLG. Pfizer Faces 2026 Trial as Brain Tumour Claims Multiply
Zantac Cancer Claims
Pfizer has been named in litigation alleging that Zantac (ranitidine) contained an NDMA impurity that increased cancer risk. Pfizer sold Zantac between 1998 and 2006 and has said the 2019 and 2020 market withdrawals did not involve any Pfizer-branded products.11Pfizer. Pfizer Statement on Zantac Litigation In 2024, Pfizer offered up to $250 million to settle thousands of Zantac cancer lawsuits, according to Reuters and the Financial Times.12Reuters. Pfizer Offers Up to $250 Million to Settle Thousands of Zantac Cancer Lawsuits
Chantix Contamination Lawsuits
Pfizer halted global Chantix (varenicline) production in June 2021 after finding that levels of the nitrosamine impurity N-nitroso-varenicline exceeded FDA guidelines. A voluntary recall of all lots followed in September 2021, and Pfizer eventually discontinued the brand-name product permanently.13FDA. Pfizer Expands Voluntary Nationwide Recall to Include All Lots of Chantix Nitrosamines are considered potential carcinogens, though the FDA characterized the cancer risk as theoretical and tied to long-term ingestion, and did not advise patients to stop taking varenicline given the health benefits of smoking cessation.14GoodRx. Chantix Production Halted
Plaintiff Daphne Walter filed a class action in U.S. District Court in Portland alleging contamination and misbranding. By late 2022 Pfizer had acknowledged 11 related suits, and a judicial panel was set to decide in December 2022 whether to consolidate them into a multidistrict litigation. Pfizer opposed consolidation.15The Lund Report. Anti-Smoking Pill, Like Cigarettes, Contained Carcinogens, Suit Alleges
Oxbryta Withdrawal
Pfizer voluntarily withdrew all lots of the sickle cell disease treatment Oxbryta (voxelotor) worldwide on September 25, 2024, and ended active clinical trials and expanded access programs. The company said clinical data showed the drug’s overall benefit no longer outweighed its risks, citing an imbalance in vaso-occlusive crises and fatal events versus placebo.16Pfizer. Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment Oxbryta The FDA confirmed the withdrawal, citing postmarketing data that showed higher rates of vaso-occlusive crisis and more deaths in the Oxbryta group compared to placebo.17FDA. FDA Alerting Patients and Health Care Professionals About Voluntary Withdrawal of Oxbryta The withdrawal has raised the prospect of future injury litigation, though no specific cases are documented in the available research.
The 2009 DOJ Off-Label Marketing Case
Pfizer’s largest resolved matter was a $2.3 billion settlement with the U.S. Department of Justice in September 2009, at the time the largest health care fraud settlement ever. Pfizer subsidiary Pharmacia & Upjohn Company Inc. pleaded guilty to a criminal charge of misbranding the anti-inflammatory drug Bextra with intent to defraud or mislead, in violation of the Food, Drug, and Cosmetic Act. The criminal fine alone exceeded $1.1 billion.18Pfizer. Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department of Justice
Bextra had been pulled from the market in 2005 over cardiovascular and skin reaction risks. The settlement also addressed off-label promotion of Zyvox, Geodon, Lyrica, and nine other Pfizer drugs. The civil piece was about $1 billion, split among Medicaid programs in 49 states and D.C., and Pfizer paid a separate $33 million to 42 states for consumer protection claims tied to Geodon.18Pfizer. Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department of Justice Federal authorities noted at the time that this was the fourth settlement between Pfizer and the government in a decade over unlawful marketing, following an earlier $450 million resolution and guilty plea over off-label promotion of gabapentin (Neurontin).19Psychiatric News. Pfizer to Pay $2.3 Billion for Illegal Marketing
The Wyeth Protonix Medicaid Case
In April 2016, Pfizer and its subsidiary Wyeth agreed to pay $784.6 million to resolve claims that Wyeth submitted false pricing data for two acid reflux drugs, Protonix Oral and Protonix IV, and underpaid Medicaid rebates from 2001 to 2006. The government alleged Wyeth gave hospitals deep discounts but did not report them, depriving Medicaid of the same pricing.20U.S. Department of Justice. Justice Department Recovers Over $4.7 Billion From False Claims Act Cases in Fiscal Year 2016
The case began with a 2003 whistleblower suit by Lauren Kieff in the District of Massachusetts. The federal government took $413.2 million and state Medicaid programs took $371.4 million. At the time it ranked as the seventh-largest False Claims Act recovery in history. Pfizer acquired Wyeth in 2009, after the alleged conduct had ended.21HHS Office of Inspector General. Wyeth and Pfizer Agree to Pay $784.6 Million to Resolve Lawsuit
Antitrust: EpiPen, Generics, and Metsera
EpiPen
Pfizer and its subsidiaries Meridian Medical Technologies and King Pharmaceuticals paid a combined $395 million to resolve two class-action antitrust suits over EpiPen pricing. A $345 million settlement resolved a 2017 multidistrict case in the District of Kansas brought by indirect purchasers (consumers, insurers, and pension funds) alleging anticompetitive conduct that drove prices up. The court gave final approval on November 17, 2021.22CNBC. Pfizer Subsidiaries Agree to Pay $345 Million in EpiPen Settlement A separate $50 million settlement resolved a 2020 direct-purchaser class action alleging that Pfizer and Mylan conspired with Teva to delay a generic EpiPen. Pfizer denied wrongdoing in both cases.23Fierce Pharma. Pfizer Agrees to Pay $50M in Another EpiPen Antitrust Settlement
Generic Drug Price-Fixing
Pfizer was named in Connecticut v. Sandoz, a multi-state case filed in 2020 in the District of Connecticut accusing dozens of generic manufacturers of price-fixing, market allocation, and bid-rigging between 2010 and 2014. Claims against Pfizer centered on Greenstone LLC, a generic subsidiary Pfizer acquired in 2003 and spun off in 2020. On June 23, 2026, Judge Michael P. Shea granted Pfizer summary judgment and dismissed all claims with prejudice, finding no evidence that Pfizer directly participated in the conduct and rejecting the theory that Greenstone acted as Pfizer’s agent.24Bloomberg Law. Pfizer Freed From US States’ Drug Price-Fixing Conspiracy Claims
Pfizer’s Own Lawsuits Over Metsera
In late 2025, Pfizer went to court as a plaintiff to block Novo Nordisk from acquiring Metsera Inc., a biotech developing GLP-1 obesity drugs. Pfizer had a deal to acquire Metsera for $4.9 billion plus $2.4 billion in milestones with early FTC clearance; Novo Nordisk countered at roughly $9 billion.25Fierce Biotech. Pfizer Sues Metsera Over Novo’s Counter-Offer
In the Delaware Court of Chancery, Pfizer alleged breach of contract, breach of fiduciary duty, and tortious interference, and sought a TRO to keep Metsera from terminating the merger agreement. On November 5, 2025, Vice Chancellor Morgan Zurn denied the TRO, finding Pfizer had not shown the Metsera board acted in bad faith or that Pfizer would suffer irreparable harm.26Pfizer. Pfizer Responds to Delaware Chancery Court Ruling Pfizer also filed federal antitrust claims in the District of Delaware under the Clayton Act and Sherman Act, calling Novo Nordisk’s bid a “capture and kill” strategy. The FTC sent a letter in November 2025 warning Metsera and Novo Nordisk that the transaction could be deemed illegal under the HSR Act. Both cases remain active.27Pfizer. Pfizer Files Federal Antitrust Claims in Second Lawsuit
Lipitor Diabetes Claims (Dismissed)
Readers researching Pfizer drug injury litigation sometimes come across the Lipitor cases; those are closed. Hundreds of suits alleged that Lipitor (atorvastatin) caused type 2 diabetes, particularly in women, and that Pfizer failed to warn. Federal cases were consolidated into a California MDL in February 2014. The MDL judge dismissed all pending product liability cases on January 25, 2016, and the Court of Appeals affirmed on June 12, 2018. No settlement or plaintiff verdict was reached, with the failure attributed to an inability to establish sufficient scientific evidence of a causal link.28Miller & Zois. Lipitor Lawsuit
Total Enforcement Picture
Across 108 enforcement actions since 2000, Pfizer’s $11.28 billion total breaks down roughly this way: about $5.6 billion for drug and medical equipment safety violations, about $3.4 billion for off-label or unapproved promotion, roughly $1.2 billion in False Claims Act violations, and about $1 billion for price-fixing and anticompetitive practices.1Good Jobs First. Pfizer Violation Tracker A significant share came from conduct at companies Pfizer later absorbed, including Wyeth, Warner-Lambert, Pharmacia, and American Home Products, whose liabilities transferred through acquisition.